Dyne Therapeutics (DYN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $14.25, -6.80% vs the prior close of $15.29.
- Volume 2.86M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
DYN slides 6.8% to $14.25, a 52-week low. Closed at $14.25, -6.80% vs the prior close of $15.29. Day range $14.14–$15.49, opened at $15.49.
DYN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — DYN slides 6.8% to $14.25, a 52-week low
- Closed at $14.25, -6.80% vs the prior close of $15.29. Day range $14.14–$15.49, opened at $15.49.
- Volume was 2.86M shares, 1.0x its 50-day average of 2.90M.
- Price is -30.6% vs its 50-day average ($20.53) and -26.6% vs its 200-day average ($19.41).
- 52-week range $14.00–$27.31; today's close sits at 2% of that range, 47.8% below the 52-week high.
Oct 15, 2026 — DYN rises 1.7% to $15.29
- Closed at $15.29, +1.66% vs the prior close of $15.04. Day range $15.04–$15.47, opened at $15.15.
- Volume was 2.07M shares, 0.7x its 50-day average of 2.90M.
- Price is -26.4% vs its 50-day average ($20.76) and -21.3% vs its 200-day average ($19.43).
- 52-week range $14.00–$27.31; today's close sits at 10% of that range, 44.0% below the 52-week high.
Oct 14, 2026 — DYN dips 1.7% to $15.04, a 6-month low, 3 down days in a row
- Closed at $15.04, -1.70% vs the prior close of $15.30. Day range $14.71–$15.41, opened at $15.11.
- Volume was 2.20M shares, 0.8x its 50-day average of 2.91M.
- Price is -28.3% vs its 50-day average ($20.98) and -22.7% vs its 200-day average ($19.45).
- 52-week range $13.88–$27.31; today's close sits at 9% of that range, 44.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — DYN slides 4.1% to $15.30
- Closed at $15.30, -4.14% vs the prior close of $15.96. Day range $15.28–$15.99, opened at $15.97.
- Volume was 3.34M shares, 1.2x its 50-day average of 2.89M.
- Price is -27.8% vs its 50-day average ($21.20) and -21.4% vs its 200-day average ($19.48).
- 52-week range $13.73–$27.31; today's close sits at 12% of that range, 44.0% below the 52-week high.
Oct 12, 2026 — DYN slides 4.1% to $15.96
- Closed at $15.96, -4.09% vs the prior close of $16.64. Day range $15.73–$16.76, opened at $16.54.
- Volume was 2.92M shares, 1.0x its 50-day average of 2.87M.
- Price is -25.4% vs its 50-day average ($21.40) and -18.2% vs its 200-day average ($19.50).
- 52-week range $13.73–$27.31; today's close sits at 16% of that range, 41.5% below the 52-week high.
Oct 9, 2026 — DYN rises 1.6% to $16.64, 3 up days in a row
- Closed at $16.64, +1.65% vs the prior close of $16.37. Day range $16.36–$17.31, opened at $16.41.
- Volume was 3.57M shares, 1.3x its 50-day average of 2.83M.
- Price is -22.9% vs its 50-day average ($21.58) and -14.8% vs its 200-day average ($19.52).
- 52-week range $13.73–$27.31; today's close sits at 21% of that range, 39.1% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — DYN rises 2.5% to $16.37 on 2.3x normal volume
- Closed at $16.37, +2.50% vs the prior close of $15.97. Day range $15.35–$16.47, opened at $15.84.
- Volume was 6.28M shares, 2.3x its 50-day average of 2.75M — unusually heavy trading.
- Price is -24.8% vs its 50-day average ($21.76) and -16.2% vs its 200-day average ($19.54).
- 52-week range $13.73–$27.31; today's close sits at 19% of that range, 40.0% below the 52-week high.
Oct 7, 2026 — DYN jumps 3.7% to $15.97
- Closed at $15.97, +3.70% vs the prior close of $15.40. Day range $15.24–$16.11, opened at $15.40.
- Volume was 3.49M shares, 1.3x its 50-day average of 2.73M.
- Price is -27.2% vs its 50-day average ($21.94) and -18.4% vs its 200-day average ($19.56).
- 52-week range $12.77–$27.31; today's close sits at 22% of that range, 41.5% below the 52-week high.
Oct 6, 2026 — DYN ends flat (-0.3%) to $15.40
- Closed at $15.40, -0.26% vs the prior close of $15.44. Day range $14.93–$15.59, opened at $15.50.
- Volume was 4.10M shares, 1.5x its 50-day average of 2.71M.
- Price is -30.4% vs its 50-day average ($22.14) and -21.3% vs its 200-day average ($19.58).
- 52-week range $12.43–$27.31; today's close sits at 20% of that range, 43.6% below the 52-week high.
Oct 5, 2026 — DYN rises 1.6% to $15.44
- Closed at $15.44, +1.58% vs the prior close of $15.20. Day range $15.08–$15.54, opened at $15.31.
- Volume was 4.38M shares, 1.6x its 50-day average of 2.72M.
- Price is -30.9% vs its 50-day average ($22.34) and -21.2% vs its 200-day average ($19.59).
- 52-week range $12.43–$27.31; today's close sits at 20% of that range, 43.5% below the 52-week high.
Oct 2, 2026 — DYN slides 3.9% to $15.20, a 6-month low, 4 down days in a row
- Closed at $15.20, -3.92% vs the prior close of $15.82. Day range $15.09–$16.03, opened at $16.03.
- Volume was 2.53M shares, 0.9x its 50-day average of 2.77M.
- Price is -32.5% vs its 50-day average ($22.52) and -22.5% vs its 200-day average ($19.61).
- 52-week range $12.33–$27.31; today's close sits at 19% of that range, 44.3% below the 52-week high.
- That makes 4 straight losses.
DYN latest news & SEC filings
Every SEC filing by or about DYN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Posner Brian S bought 2,500 shares at $16.00 (≈$40.00K) on Oct 2, 2026; now holds 27,000
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 8, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Friedl-Naderer Johanna sold 185 shares at $18.88 (≈$3.49K) on Sep 8, 2026
- Friedl-Naderer Johanna sold 185 shares at $18.88 (≈$3.49K) on Sep 8, 2026
- Friedl-Naderer Johanna sold 185 shares at $18.88 (≈$3.49K) on Sep 8, 2026
- Friedl-Naderer Johanna sold 185 shares at $18.88 (≈$3.49K) on Sep 8, 2026
- Friedl-Naderer Johanna sold 900 shares at $24.35 (≈$21.91K) on Sep 4, 2026
- Friedl-Naderer Johanna sold 900 shares at $24.35 (≈$21.91K) on Sep 4, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kerr Douglas sold 1,290 shares at $18.88 (≈$24.36K) on Sep 8, 2026
- Kerr Douglas sold 1,290 shares at $18.88 (≈$24.36K) on Sep 8, 2026
- Kerr Douglas sold 1,290 shares at $18.88 (≈$24.36K) on Sep 8, 2026
- Kerr Douglas sold 1,290 shares at $18.88 (≈$24.36K) on Sep 8, 2026
- Kerr Douglas sold 3,745 shares at $24.35 (≈$91.19K) on Sep 4, 2026
- Kerr Douglas sold 3,745 shares at $24.35 (≈$91.19K) on Sep 4, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cox John sold 5,658 shares at $18.88 (≈$106.82K) on Sep 8, 2026
- Cox John sold 5,658 shares at $18.88 (≈$106.82K) on Sep 8, 2026
- Cox John sold 5,658 shares at $18.88 (≈$106.82K) on Sep 8, 2026
- Cox John sold 5,658 shares at $18.88 (≈$106.82K) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$178.56M (prior year -$110.86M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.08 (prior year -$0.97) (loss widened vs Jun 30, 2025)
Jul 28, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 22, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade DYN
- Last results release: Jul 29, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 2, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Oct 28, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.36% (largest 6.8%).
- Liquidity: about 3.19M shares (≈$45.44M) trade per day on average.
- 52-week position: $14.25 vs a range of $14.00–$27.31 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: John Cox sold 5,658 shares on Sep 8, 2026.
- Latest filings: 8-K Sep 29, 2026; 8-K Jul 29, 2026; 10-Q Jul 29, 2026.
- Share count: 186.75M shares outstanding (Jul 24, 2026), +31.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
DYN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 15.49 | 15.49 | 14.14 | 14.25 | 2.86M |
| Oct 15, 2026 | 15.15 | 15.47 | 15.04 | 15.29 | 2.07M |
| Oct 14, 2026 | 15.11 | 15.41 | 14.71 | 15.04 | 2.20M |
| Oct 13, 2026 | 15.97 | 15.99 | 15.28 | 15.30 | 3.34M |
| Oct 12, 2026 | 16.54 | 16.76 | 15.73 | 15.96 | 2.92M |
| Oct 9, 2026 | 16.41 | 17.31 | 16.36 | 16.64 | 3.57M |
| Oct 8, 2026 | 15.84 | 16.47 | 15.35 | 16.37 | 6.28M |
| Oct 7, 2026 | 15.40 | 16.11 | 15.24 | 15.97 | 3.49M |
| Oct 6, 2026 | 15.50 | 15.59 | 14.93 | 15.40 | 4.10M |
| Oct 5, 2026 | 15.31 | 15.54 | 15.08 | 15.44 | 4.38M |
| Oct 2, 2026 | 16.03 | 16.03 | 15.09 | 15.20 | 2.53M |
| Oct 1, 2026 | 16.01 | 16.28 | 15.52 | 15.82 | 3.70M |
| Sep 30, 2026 | 16.05 | 16.80 | 15.92 | 16.11 | 4.46M |
| Sep 29, 2026 | 16.40 | 16.55 | 15.97 | 16.21 | 2.29M |
| Sep 28, 2026 | 15.86 | 16.43 | 15.63 | 16.34 | 2.31M |
| Sep 25, 2026 | 16.62 | 16.75 | 16.02 | 16.03 | 1.61M |
| Sep 24, 2026 | 16.09 | 16.65 | 15.88 | 16.51 | 3.20M |
| Sep 23, 2026 | 17.08 | 17.08 | 16.18 | 16.23 | 2.64M |
| Sep 22, 2026 | 17.39 | 17.59 | 17.06 | 17.14 | 2.63M |
| Sep 21, 2026 | 17.31 | 17.59 | 16.75 | 17.12 | 3.22M |
About Dyne Therapeutics
Dyne Therapeutics (DYN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WALTHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1818794.
DYN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| John Cox | CEO & President | Sep 8, 2026 |
| Barry E Greene | Director | Jun 23, 2026 |
| Edward Hurwitz | Director | Jun 9, 2026 |
| Carlo Incerti | Director | Jun 9, 2026 |
| Vikram Karnani | Director | Dec 23, 2025 |
| Dirk Kersten | Director | Jul 29, 2026 |
| David Charles Lubner | Director | Jun 9, 2026 |
| Brian S Posner | Director | Jun 9, 2026 |
| Jason P Rhodes | Director | Aug 17, 2026 |
| Catherine Stehman-Breen | Director | Jun 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| John Cox | CEO & President | Sep 8, 2026 |
| Johanna Friedl-Naderer | Chief Commercial Officer | Sep 8, 2026 |
| Douglas Kerr | Chief Medical Officer | Sep 8, 2026 |
| Erick Lucera | Chief Financial Officer | Aug 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 8, 2026 | John Cox | Sale | 5,658 | $18.88 |
| Sep 8, 2026 | John Cox | Sale | 5,658 | $18.88 |
| Sep 8, 2026 | John Cox | Sale | 5,658 | $18.88 |
| Sep 8, 2026 | John Cox | Sale | 5,658 | $18.88 |
| Sep 8, 2026 | Johanna Friedl-Naderer | Sale | 185 | $18.88 |
| Sep 8, 2026 | Johanna Friedl-Naderer | Sale | 185 | $18.88 |
| Sep 8, 2026 | Johanna Friedl-Naderer | Sale | 185 | $18.88 |
| Sep 8, 2026 | Johanna Friedl-Naderer | Sale | 185 | $18.88 |
| Sep 8, 2026 | Douglas Kerr | Sale | 1,290 | $18.88 |
| Sep 8, 2026 | Douglas Kerr | Sale | 1,290 | $18.88 |
| Sep 8, 2026 | Douglas Kerr | Sale | 1,290 | $18.88 |
| Sep 8, 2026 | Douglas Kerr | Sale | 1,290 | $18.88 |
| Sep 4, 2026 | Johanna Friedl-Naderer | Sale | 900 | $24.35 |
| Sep 4, 2026 | Johanna Friedl-Naderer | Sale | 900 | $24.35 |
| Sep 4, 2026 | Johanna Friedl-Naderer | Sale | 900 | $24.35 |
DYN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-446.21M | -3.47 | $-403.21M |
| Dec 31, 2024 | — | $-317.42M | -3.37 | $-292.37M |
| Dec 31, 2023 | — | $-235.94M | -3.95 | $-188.16M |
| Dec 31, 2022 | — | $-168.10M | -3.23 | $-153.65M |
| Dec 31, 2021 | — | $-149.29M | -2.93 | $-119.56M |
Latest balance sheet: total assets $994.01M, total liabilities $291.86M, cash $676.11M (as of Jun 30, 2026).
DYN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 29, 2026 | 8-K Item 2.02 (results) | $25.10 |
| May 11, 2026 | 8-K Item 2.02 (results) | $18.46 |
| Mar 2, 2026 | 8-K Item 2.02 (results) | $16.15 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $17.46 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $20.90 |
| Jul 28, 2025 | 8-K Item 2.02 (results) | $9.31 |
| May 8, 2025 | 8-K Item 2.02 (results) | $11.30 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $13.17 |
| Jan 10, 2025 | 8-K Item 2.02 (results) | $15.87 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $29.33 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on DYN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.